Addressing Diabetes and Cardiovascular Disease Prevention: Key Insights

Overview

This report highlights the intersection of type 2 diabetes (T2D) and cardiovascular disease (CVD), emphasizing the high prevalence of undiagnosed diabetes in myocardial infarction patients and the importance of improved screening. It also reviews advances in cardiovascular risk prediction models, the impact of heart rate variability on mortality, and the evolving role of pharmacological treatments such as SGLT2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular events.

Background

Cardiovascular disease remains a leading cause of morbidity and mortality among patients with type 2 diabetes. Early diagnosis of diabetes in patients presenting with cardiovascular events is critical for timely intervention. Accurate cardiovascular risk prediction models tailored for T2D populations are essential for guiding preventive strategies. Additionally, novel pharmacotherapies have demonstrated cardioprotective effects, reshaping treatment paradigms in this high-risk group.

Data Highlights

Key Findings

• Approximately 17% of patients hospitalized for myocardial infarction are newly diagnosed with diabetes, highlighting the need for improved diabetes screening.
• Cardiovascular risk prediction models specifically developed for T2D, such as SCORE2-diabetes and ADVANCE, outperform general population models.
• In elderly T2D patients, the CARE-DM model accurately predicts 5–10-year cardiovascular risk using clinical and treatment data.
• Low 24-hour and nocturnal heart rate variability is strongly associated with increased cardiovascular and all-cause mortality in diabetes.
• SGLT2 inhibitors are widely used and trusted in patients with heart failure and T2D, though use of mineralocorticoid receptor antagonists and renin–angiotensin system inhibitors is lower in this group.
• GLP-1 receptor agonist albiglutide reduces major adverse cardiovascular events without increasing atrial fibrillation risk.

Clinical Implications

Clinicians should prioritize screening for diabetes in patients presenting with cardiovascular events to enable early intervention. Utilizing validated T2D-specific cardiovascular risk models can improve risk stratification and guide personalized preventive strategies. The demonstrated cardiovascular benefits and safety profiles of SGLT2 inhibitors and GLP-1 receptor agonists support their integration into treatment regimens for patients with T2D and cardiovascular disease.

Conclusion

Addressing the intertwined challenges of diabetes and cardiovascular disease requires enhanced screening, accurate risk prediction, and optimized use of cardioprotective therapies. These strategies collectively hold promise to reduce morbidity, mortality, and societal burden associated with these conditions.

References

1. Douelrachad et al. 2024 -- New diagnosis of diabetes in patients with myocardial infarction or stroke: a systematic review and meta-analysis
2. Abushanab et al. 2024 -- The reduction of the productivity burden of cardiovascular disease by improving risk factor control among Australians with type 2 diabetes
3. Enguita-Germán et al. 2024 -- External validation of cardiovascular risk scores in patients with type 2 diabetes using the Spanish population-based CARDIANA cohort
4. Aponte Ribero et al. 2024 -- Development and validation of the CARE-DM model to predict cardiovascular risk in older persons with type 2 diabetes
5. Nesti et al. 2024 -- Circadian heart rate fluctuations predict cardiovascular and all-cause mortality in Type 2 and Type 1 diabetes
6. Musella et al. 2024 -- Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and type 2 diabetes
7. Krychtiuk et al. 2024 -- Albiglutide and atrial fibrillation in patients with type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial